Breast Cancer Trial Results
Boost Radiation Beneficial in Early-Stage Breast Cancer
(Posted: 07/11/2007) - In women with early-stage breast cancer who had been treated with breast-conserving lumpectomy and radiation, an additional "boost" dose of radiation to the original tumor site reduced the risk of cancer coming back in the same breast, though it did not help them live longer, according to the Aug. 1, 2007, Journal of Clinical Oncology.
Ovary-Suppressing Drugs Can Prevent Return of Breast Cancer
(Posted: 06/25/2007) - In premenopausal women with hormone-sensitive breast cancer, drugs that stop the ovaries from functioning - thus shutting off the body's main source of the hormone estrogen - reduced the rates of relapse and of death following relapse when given in addition to tamoxifen, chemotherapy, or both, according to the May 19, 2007, Lancet.
Studies Affirm Tamoxifen's Long-Term Preventive Benefit
(Posted: 03/07/2007) - Long-term follow-up data from two cancer prevention trials have confirmed that women at high risk for breast cancer continue to receive a risk-reduction benefit from tamoxifen years after they have stopped taking it, according to the Feb. 21, 2007, Journal of the National Cancer Institute.
Study Confirms Risk of Bone Loss for Patients Taking Exemestane
(Posted: 02/14/2007) - Women who switched to the drug exemestane after taking tamoxifen to prevent a breast cancer relapse lost more bone density and had a higher risk of bone fractures than women who continued taking tamoxifen, according to a report published online Jan. 26, 2007, by Lancet Oncology.
(Posted: 07/11/2007) - In women with early-stage breast cancer who had been treated with breast-conserving lumpectomy and radiation, an additional "boost" dose of radiation to the original tumor site reduced the risk of cancer coming back in the same breast, though it did not help them live longer, according to the Aug. 1, 2007, Journal of Clinical Oncology.
Ovary-Suppressing Drugs Can Prevent Return of Breast Cancer
(Posted: 06/25/2007) - In premenopausal women with hormone-sensitive breast cancer, drugs that stop the ovaries from functioning - thus shutting off the body's main source of the hormone estrogen - reduced the rates of relapse and of death following relapse when given in addition to tamoxifen, chemotherapy, or both, according to the May 19, 2007, Lancet.
Studies Affirm Tamoxifen's Long-Term Preventive Benefit
(Posted: 03/07/2007) - Long-term follow-up data from two cancer prevention trials have confirmed that women at high risk for breast cancer continue to receive a risk-reduction benefit from tamoxifen years after they have stopped taking it, according to the Feb. 21, 2007, Journal of the National Cancer Institute.
Study Confirms Risk of Bone Loss for Patients Taking Exemestane
(Posted: 02/14/2007) - Women who switched to the drug exemestane after taking tamoxifen to prevent a breast cancer relapse lost more bone density and had a higher risk of bone fractures than women who continued taking tamoxifen, according to a report published online Jan. 26, 2007, by Lancet Oncology.
